title: Risk of Intussusception After Rotavirus Vaccination: Meta-analysis of Postlicensure Studies.
abstract: BACKGROUND
  Postlicensure surveillance studies suggest a small temporal increase in the risk for intussusception with both currently available rotavirus vaccines (RV1; Rotarix, GSK and RV5; RotaTeq, Merck & Co., Inc.). This meta-analysis was undertaken to provide a single overall estimate of the relative risk of intussusception during the 7-day period after administration of RV1 and RV5.
  
  
  METHODS
  Meta-analysis based on estimates of relative risk and corresponding 95% confidence intervals from 5 postlicensure studies providing an estimate of risk of intussusception during the 7-day period after administration of dose 1 and/or dose 2 of RV1 and/or RV5, based on active and/or passive surveillance, for confirmed intussusception cases (Brighton or other method of case confirmation). For each vaccine, the relative risk of intussusception was estimated postdose 1 and postdose 2. Results were pooled using the inverse variance method using both fixed-effect and random-effect models.
  
  
  RESULTS
  The overall estimate of relative risk of intussusception during the 7 days postdose 1 was 5.4 (95% confidence interval: 3.9-7.4, 3 studies) for RV1 and 5.5 (3.3-9.3, 3 studies) for RV5. The overall estimate of relative risk of intussusception during the 7 days postdose 2 was 1.8 (1.3-2.5, 4 studies) for RV1 and 1.7 (1.1-2.6, 3 studies) for RV5.
  
  
  CONCLUSIONS
  This meta-analysis showed a similar increased risk of intussusception, during the first 7 days after administration of dose 1 and, to a lesser extent, dose 2, for both currently available rotavirus vaccines. This suggests that intussusception may be a class effect of currently available oral rotavirus vaccines.
authors.affiliation: From *GlaxoSmithKline Vaccines, Wavre, Belgium; †GlaxoSmithKline, Philadelphia, PA; and ‡Medical Research Unit on Infectious Diseases, Pediatrics Hospital, National Medical Center-Century-XXI, Mexican Institute of Social Security (IMSS), Mexico City, D.F., Mexico.
authors.forename: Dominique
authors.initials: D
authors.lastname: Rosillon
authors.forename: Hubert
authors.initials: H
authors.lastname: Buyse
authors.forename: Leonard R
authors.initials: LR
authors.lastname: Friedland
authors.forename: Su-Peing
authors.initials: SP
authors.lastname: Ng
authors.forename: F Raúl
authors.initials: FR
authors.lastname: Velázquez
authors.forename: Thomas
authors.initials: T
authors.lastname: Breuer
mesh_terms: D002675:Child, Preschool; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D007443:Intussusception / Q000139:chemically induced* / Q000453:epidemiology*; D011358:Product Surveillance, Postmarketing; D018570:Risk Assessment; D022243:Rotavirus Vaccines / Q000008:administration & dosage / Q000009:adverse effects*; D014611:Vaccination / Q000009:adverse effects* / Q000379:methods; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: C492457:RIX4414 vaccine; C492535:RotaTeq; D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated